The Life Sciences Catalyst
Developed through our industry insights and deep relationships across the local and global ecosystem, the Deloitte Life Sciences Catalyst exists to solve the business challenges that keep life sciences leaders and innovators up at night.
Via a virtual events programme, a database of whitepapers and a business surgery programme, the Life Sciences Catalyst facilitates connections between people, businesses and investors to support companies, regardless of their evolutionary stage.
Based in the heart of Cambridge, but working virtually, we are ready to help you harness the business opportunities ahead.
Contact us to start the conversation.
Join the Catalyst
The Life Sciences Catalyst offers a collaborative platform for growing Biotech and Medtech companies, Pharmaceutical companies, Technology companies and prospective investors to come together to tackle the big challenges facing us all.
In addition to regular virtual events, the Life Sciences Catalyst will provide access to a range of other benefits:
Life Sciences Knowledge Portal: An online database of relevant whitepapers and insight from industry experts and the Deloitte Centre for Health Solutions
Business Surgery: A drop in surgery, where industry experts will be available on hand to examine individual business challenges and offer support.
Virtual Growth Labs: A virtual collaborative lab which promotes shared industry learning and connections between organisations from all areas of the Life Sciences and Healthcare ecosystem.
Events and Insights
On 5 October, we hosted a webinar on digitisation. We were joined by Amazon Web Services, Healthcare and Life Sciences Leader, Himanshu Jain. Scientific data is at the core of every Life Sciences company and organisation. A key challenge many face is getting this valuable data out of the lab and into the decision making processes.
In this webinar we reviewed the common challenges facing labs, how digital solutions can overcome those challenges and discuss how lab digitisation can accelerate your product on its journey from bench to patient.
How emerging biotechs are exploring the opportunities of out-licensing?
Increasingly, emerging biotech companies enter Europe through partnerships and out-licencing deals due to the lower risk, less cost, and increased speed to market – all of which enable a successful first launch. However, for the right companies, go-alone remains attractive to generate the highest returns.
Following our latest report, hear from Hanno Ronte, Emma Dabbs and Rob Finn discussing the latest trends, choices, and tradeoffs to consider.
European expansion: How emerging biotechs are exploring the opportunities of out-licencing
The go-to-market strategies deployed by emerging biotechs to launch their first products into Europe have changed in the last two years. Instead of building their own infrastructure, emerging biotechs are primarily commercialising their products through out-licencing agreements.
Building a Biotech Valuation Webinar
This webinar explored:
- • What are the business model considerations for biotech and pharma tech?
- • How do the different business models generate revenue?
- • What are the measurable risks to assess for valuing a platform based business?
- • What are the key valuation considerations for biotech and pharma tech?
In recent years, companies operating in the Life Sciences and Healthcare (LSHC) sector are more and more participating in open innovation to overcome various R&D and commercial challenges. The concept of open innovation involves sourcing new technologies, skills, and knowledge from third parties versus adopting more traditional or closed in-house development models. Overall, biopharma assets sourced via open innovation approaches are currently demonstrating a higher probability of later-phase clinical success compared to those from closed model product development. For large pharma companies this is leading to more cost and time effective product development and is shortening the time to market as well as providing wider access to talent, new technologies, broader geographies, and different therapeutic areas. For smaller pharma and biotech companies, open innovation is leading to increased partnerships and out-licensing opportunities, but this is not without challenges. To help smaller LSHC companies better navigate open innovation, Deloitte’s IP Advisory team has identified key areas to address to ensure more successful outcomes including when to seek a partner, identifying the right partner, preparing materials, and deal negotiations skills.
Fundraising in the life sciences from a female perspective
On Thursday 10 November, we hosted a round table discussion webinar exploring the fund raising experiences for female founders and female business leaders, the important role of IP rights, and current programs designed to help with both. The panellists discussed the current climate for female led businesses and their fundraising experiences and shared lessons they have learnt. The Deloitte IP team provided background on the benefits of owning IP and having an IP strategy/story when seeking funding and what barriers to entry female innovators tend to face.
The panel shared current government programs dedicated to helping address access to funding and IP protection support to women innovators. In addition, we were joined by Sarah King who is the CEO and founder of Radikl who is dedicated to helping raise funds for female led businesses and she shared her vision for helping women founders thrive.
Workplace real estate, the good, the bad and the crusade for talent
Thank you to everyone that joined us on the 29 September 2022. In a post pandemic environment organisations across all sectors are redefining the role of the workplace, conversely employees as consumers of space are re-assessing what they want from the workplace. The life sciences sector is no exception, with vast and often complex real estate portfolios, organisations are facing a challenge in how they create a fit for purpose environment for their employees that can effectively deliver value against business and employee requirements. Hear from the experience of our client and practitioner panel on how global life sciences organisations are battling this challenge and the steps they are taking to create a workplace for the future. You can re watch this webinar below.
Key legal issues in Health Technology in M&A
In this webcast we welcome Glafkos Tombolis and Jeremy Harris talking about key legal issues in health technology, use of data and the impact of the UK’s new national security legislation on healthcare M&A involving AI and synthetic biology.
How will AI, Automation and Technology impact the clinical workforce
On Wednesday 20 July we were joined by an expert panel talking about how AI, Automation and Technology impacts clinicians all day, in all aspects of their lives, from AI to review diagnostics through to automation of basic admin tasks. Thanks to everyone who joined this month’s Life Sciences Catalyst webinar and our guest panellists who gave their insights into how to manage these impacts, drive and shape the technologies and how the clinical workforce needs to adapt to meet these needs going forward.
How to Innovate with the NHS
19 May at 4pm
Innovating with the NHS can be hard. Such a large organisation, with significant financial and operational constraints can seem difficult to engage with.
Do we talk to clinicians, commissioners, finance directors or in reality it is all of these teams? Do we focus nationally, locally or perhaps both? What innovation support is available to SMEs and how can we access that support?
Please listen again to our webinar as we bring together a community who have been successful in innovating.
Business Transformation - ERP - When to move?
31 March 2022 at 10.00am
This webinar looked at how to run an effective ERP selection and implementation process. Insights were shared around the current ERP market trends and practical considerations.
The Future of Regulation within the Medical Devices industry
Join Life Sciences Catalyst Lead, Fran Cousins, guests, Graeme Tunbridge and John Brennan and Deloitte UK MedTech Practice Lead, Andy Flockhart discuss MedTech Regulatory trends, key considersations for life sciences companies with products in development, Sustainability and ESC and more!
Next Generation Therapies
Listen again to Life Sciences Catalyst team on 20 October at 13:30 BST.
Cell and gene therapies have the potential to revolutionise medical care, by eliminating the underlying cause of genetic and acquired diseases. It is one of the most exciting biopharma segments with relatively recent ground-breaking scientific advances driving rapid growth, and with staggering predictions for the future success of the industry. Yet, the wider economics of delivering next gen therapies - including payment models and affordability – are highly debated and not well understood.
As well as industry trends and future expectations, the team discussed how to navigate market access and reimbursement processes and the role of innovative contracting; considerations for the delivery of cell and gene therapies from a healthcare system perspective and overcoming the nuanced challenges in next gen R&D and realising a return on investment.
Deloitte Life Sciences Catalyst – Anniversary Webinar – The Future of Genomics
30 September 2021 16.00pm - 17.00pm. BST
Life Sciences Catalyst lead partner, Fran Cousins was joined by an amazing panel of senior leaders in the industry; Dame Sue Hill, Chief Scientific Officer for England, Dr David Bentley, CSO of Illumina, Dr David Atkins, CEO of Congenica, Dr Julia Wilson, Associate Director, Wellcome Sanger Institute and Chris Cowles, Partner, Withers. Mike Standing, Deloitte Partner was panel chair.
The Insight Driven Organisation
Life Sciences organisations are experiencing pervasive challenges across their value chains. Watch on demand the Deloitte Life Sciences Catalyst team review the transformative ways to cognitise the life sciences value chain.
Advancing Innovation from Abroad: Investing in Life Sciences in China and the UK
Watch on demand as a panel of experts discusses the UK investment in the Chinese life sciences sector, including what investors are looking for, the opportunities and pitfalls for investing in China.
Third Party Management in Life Sciences: Balancing responsibility, resilience and cost
Watch on demand as Deloitte experts delve into how to build resilience into your third party interactions, and manage risk whilst controlling costs.
Intellectual Property Strategy for Life Sciences Companies: Identifying, capturing and protecting your intellectual property
Watch on demand as our panel of industry leaders discuss types of intellectual property, ways to protect strategic innovations, and risks to be aware of.
LSHC Predictions 2025
Watch on demand as our panel of industry thought leaders discuss what is ahead for the Life Sciences and Healthcare ecosystem in our predictions for 2025.
Tax Incentives and Intellectual Property: Things Life Sciences Companies Need to Know
Join our webinar, as Deloitte experts discuss the intersection of intellectual property and cash tax savings, as well as critical tax pitfalls to avoid.
Welcome to the Life Sciences Catalyst: Virtual Launch and Industry Leader Panel
Join Deloitte, Sir Mene Pangalos, Dr Andy Richards and Dr Susan Windham-Bannister as they explore the challenges facing the UK life sciences sector today
The Future of Medtech with CMR Surgical
Join CMR Surgical as we analyse their impressive journey so far, forward strategy and the key issues facing the Medtech industry
To connect with the Life Sciences Catalyst community and hear about relevant industry news, please join our LinkedIn group.
European expansion: How COVID-19 has impacted the way emerging biotechs commercialise their drugs
The go-to-market strategies deployed by emerging biotechs to launch their first products into Europe have changed in the last two years. Instead of building their own infrastructure, emerging biotechs are primarily commercialising their products through, out-licencing, partnerships, or global biopharma buy-outs.
Changes to the Finance Act impacting R&D claims for life sciences companies
Life sciences companies have been benefiting from the R&D tax relief schemes, with the incentive being invested in the innovative activities these companies have claimed.
The future unmasked
Learn what the future holds for the life sciences and healthcare industries in our set of ten predictions.
Intelligent Clinical Trials
AI technologies can bring many benefits to clinical trials, including improved design, faster analysis of results and supporting approval through real-world evidence.
Measuring the return from pharmaceutical innovation
Our tenth annual report, analyses returns on innovation for biopharma companies and looks at the trends and future of the industry.
Powering drug discovery with AI
AI-enabled solutions are able to transform drug discovery, and enable the development of more precise and effective targeted treatments.
Biotech in a Box
For small to mid-cap life sciences companies, navigating the business life cycle in order to grow can be challenging. Our ‘one-stop shop’ can help.
Unlocking R&D productivity
Understanding the potential for R&D-driven acquisitions to impact R&D productivity
Realising a biotech’s potential
What is required to scale successfully?
Biotech’s presence in overall biopharma research and development has been increasing in recent years with a leading role in developing COVID-19 vaccines or treatments today.
Life Sciences Connect
Our podcast explores the big issues, the emerging trends and the cutting edge innovations that are shaping the Life Sciences industry. Each month, we will connect with industry experts and leaders from the Biotech, Pharmaceutical and Medical Devices industries to discuss how key trends, explored in our research reports, are charting a new, sustainable future for the Life Sciences Industry.
Partner, Risk Advisory
Senior Manager, Consulting
Senior Manager, Clients and Industries
Dr Nate Lee
Senior Consultant, Consulting